Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bipolar Androgen Therapy Plus Olaparib in Patient With Castration-Resistant Prostate Cancer

NCT03516812 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03516812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03516812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bipolar Androgen Therapy Plus Olaparib in Patient With Castration-Resistant Prostate Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
August 29, 2018
Completion date
April 12, 2024
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, prostate adenocarcinoma